| Lonza Group AG | 328.30 |
| Date/Time | 06/28 / 17:20 |
| Chg. / Chg.(%) | - / |
| Bid | 312.80 / 169 |
| Ask | 332.90 / 1000 |
| Open | 323.80 |
| Previous Close | 324.30 |
| High | 328.50 |
| Low | 322.50 |
| Volume [CHF] | 15,621,186.95 |
| Volume [Units] | 47,868 |
| Price fixings | 1873 |
| ISIN | CH0013841017 |
| Security | LONN/Z |
| Exchange | Cboe Europe CXE |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| SIX Swiss Ex.. | 334.30 |  |
215,947 |
| London Inter.. | 334.30 | |
9,652 |
| Lang & Schwa.. | 306.000 | |
|
| Nasdaq Other.. | 330.1400 |  |
22 |
| Cboe Europe .. | 328.30 | 47,868 | |
| Turquoise | 328.30 | |
18,782 |
| Cboe Europe .. | 328.00 | 12,923 | |
| TradeGate | 294.000 | 298 | |
| Stuttgart | 294.000 | 135 | |
| Frankfurt | 293.9000 | 63 | |
| Düsseldorf | 291.20 | 0 | |
| München | 291.30 | 0 | |
| Berlin | 296.90 | 0 | |
| Hamburg | 291.30 | 0 | |
| gettex | 296.100 | ||
| Singapore | 79.97 | 500 | |
| EUREX | Options | ||
News
- Global Primary Cells Market Analysis, Trends, and Forecasts Report 2019
10/30/2019 / 11:17 - GlobeNewswire - Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Immuno-oncology, Genomic Blizzard, Technology Convergence, The Insurance Effect
10/29/2019 / 11:55 - GlobeNewswire - Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
10/24/2019 / 15:34 - GlobeNewswire - Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
10/17/2019 / 00:17 - GlobeNewswire - Prevail Therapeutics and Lonza Establish Strategic Collaboration to Develop and Manufacture Prevail's Novel AAV9 Gene Therapy Programs for Patients with Neurodegenerative Diseases
10/08/2019 / 08:00 - GlobeNewswire
Real-time